Terms: = Kidney tumors AND PAM50
4 results:
1. pam50 and Beyond: When Will Tissue Transcriptomics Guide Clinical Decision-making?
Haywood SC; Gupta S; Heemers HV
Eur Urol Focus; 2022 Jul; 8(4):916-918. PubMed ID: 36031559
[TBL] [Abstract] [Full Text] [Related]
2. Pan-cancer application of a lung-adenocarcinoma-derived gene-expression-based prognostic predictor.
Nacer DF; Liljedahl H; Karlsson A; Lindgren D; Staaf J
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 33971670
[TBL] [Abstract] [Full Text] [Related]
3. A comparative study of PCS and pam50 prostate cancer classification schemes.
Yoon J; Kim M; Posadas EM; Freedland SJ; Liu Y; Davicioni E; Den RB; Trock BJ; Karnes RJ; Klein EA; Freeman MR; You S
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):733-742. PubMed ID: 33531653
[TBL] [Abstract] [Full Text] [Related]
4. Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy.
Zhao SG; Chang SL; Erho N; Yu M; Lehrer J; Alshalalfa M; Speers C; Cooperberg MR; Kim W; Ryan CJ; Den RB; Freedland SJ; Posadas E; Sandler H; Klein EA; Black P; Seiler R; Tomlins SA; Chinnaiyan AM; Jenkins RB; Davicioni E; Ross AE; Schaeffer EM; Nguyen PL; Carroll PR; Karnes RJ; Spratt DE; Feng FY
JAMA Oncol; 2017 Dec; 3(12):1663-1672. PubMed ID: 28494073
[TBL] [Abstract] [Full Text] [Related]
